Michael Fuchs

Author PubWeight™ 68.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009 3.48
2 Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010 2.97
3 Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013 2.82
4 Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012 2.43
5 The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011 2.37
6 Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012 1.97
7 The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 2013 1.92
8 Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2011 1.85
9 Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011 1.84
10 Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012 1.75
11 Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013 1.66
12 Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2010 1.58
13 Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013 1.51
14 ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013 1.44
15 Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008 1.20
16 Limit theorems for patterns in phylogenetic trees. J Math Biol 2009 1.16
17 Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014 1.11
18 Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2012 1.09
19 Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011 1.08
20 Redox self-sufficient biocatalyst network for the amination of primary alcohols. Angew Chem Int Ed Engl 2012 0.99
21 Legal and ethical consequences of international biobanking from a national perspective: the German BMB-EUCoop project. Eur J Hum Genet 2009 0.98
22 Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008 0.92
23 Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. J Clin Oncol 2013 0.92
24 Driving simulation can improve insight into impaired driving skills in cirrhosis. Dig Dis Sci 2011 0.92
25 Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013 0.92
26 Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl 2012 0.90
27 Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010 0.90
28 The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis 2012 0.90
29 The LIFE child study: a life course approach to disease and health. BMC Public Health 2012 0.88
30 CNS involvement in Hodgkin's lymphoma. J Clin Oncol 2007 0.87
31 Clinical results of absorbable plates for displaced metacarpal fractures. J Hand Surg Am 2007 0.87
32 A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008 0.87
33 Social withdrawal after laryngectomy. Eur Arch Otorhinolaryngol 2009 0.87
34 Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010 0.86
35 Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009 0.86
36 Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 2009 0.86
37 The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. Int J Cancer 2007 0.86
38 Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J Hepatol 2012 0.85
39 Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis 2014 0.85
40 Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013 0.84
41 Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosis. Gastroenterol Hepatol (N Y) 2010 0.84
42 Hodgkin's lymphoma: current treatment strategies and novel approaches. Expert Rev Hematol 2008 0.83
43 Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011 0.83
44 Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 2014 0.83
45 Microwave-assisted cross-coupling and hydrogenation chemistry by using heterogeneous transition-metal catalysts: an evaluation of the role of selective catalyst heating. Chemistry 2009 0.82
46 Introducing an in situ capping strategy in systems biocatalysis to access 6-aminohexanoic acid. Angew Chem Int Ed Engl 2014 0.82
47 A comparative analysis of biomedical research ethics regulation systems in Europe and Latin America with regard to the protection of human subjects. J Med Ethics 2010 0.81
48 Artificial multi-enzyme networks for the asymmetric amination of sec-alcohols. Chemistry 2013 0.81
49 The substrate tolerance of alcohol oxidases. Appl Microbiol Biotechnol 2015 0.81
50 Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice. Biochem J 2002 0.81
51 One-pot deracemization of sec-alcohols: enantioconvergent enzymatic hydrolysis of alkyl sulfates using stereocomplementary sulfatases. Angew Chem Int Ed Engl 2013 0.81
52 Migration pattern of a femoral short-stem prosthesis: a 2-year EBRA-FCA-study. Arch Orthop Trauma Surg 2014 0.81
53 Safety and tolerability of agomelatine: focus on hepatotoxicity. Curr Drug Metab 2014 0.80
54 Arg64 variant of the beta3-adrenergic receptor is associated with gallstone formation. Am J Gastroenterol 2007 0.79
55 Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutrition 2004 0.78
56 Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice. Biochim Biophys Acta 2004 0.78
57 Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma. Leuk Lymphoma 2010 0.77
58 Auditory processing disorders with and without central auditory discrimination deficits. J Assoc Res Otolaryngol 2014 0.77
59 Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol 2011 0.76
60 Differences between hepatic and biliary lipid metabolism and secretion in genetically gallstone-susceptible and gallstone-resistant mice. Chin Med J (Engl) 2002 0.76
61 Speech rehabilitation during the first year after total laryngectomy. Head Neck 2012 0.76
62 Endoscopic findings of the external ear canal in a group of clinically normal horses and horses with head shaking or vestibular disease. Berl Munch Tierarztl Wochenschr 2014 0.75
63 Changes in regional energy metabolism after cortical cold lesion in the rat brain. J Mol Neurosci 2002 0.75
64 Evaluation of the progress of therapy in patients with cleft lip, jaw and palate, using voice analysis--a pilot study. J Orofac Orthop 2008 0.75
65 [Perceived stigmatisation following laryngectomy]. Psychother Psychosom Med Psychol 2007 0.75
66 Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Transfus Apher Sci 2007 0.75
67 The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. Expert Rev Anticancer Ther 2010 0.75
68 [Physical fitness in space: measures to prevent muscular atrophy]. Sportverletz Sportschaden 2002 0.75
69 [Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials]. Onkologie 2013 0.75
70 Motivation as a predictor of speech intelligibility after total laryngectomy. Head Neck 2012 0.75
71 Brain Integrity Changes underlying Cognitive and Functional Recovery Postliver Transplant Continue to Evolve Over 1 Year. Transplantation 2017 0.75